. Author manuscript; available in PMC: 2018 Mar 30.

Published in final edited form as: JAMA Oncol. 2017 Nov 9;3(11):e170231. doi: 10.1001/jamaoncol.2017.0231

Table 3.

Patient characteristics by best PSA response

	CR	PR	NO/NA
Age (median, range) years	64 (51, 72)	63 (55, 79)	71 (39, 85)
Entry PSA (median, Q1 Q3) ng/dL	11.5 (5.1, 13.4)	12.2 (7.4, 20.8)	50.6 (22.9, 266.9)
Testosterone (median, range) ng/dL	10 (3, 36)	17 (3, 40)	13.8 (3, 50)
Days from ADT to Registration (median, range)	137 (13, 308)	116 (44, 316)	54 (10, 371)

Abbreviations: ADT, Androgen Deprivation Therapy; CR, Complete response with a PSA of ≤ 0.2 ng/ml; NO/NA, no response or not applicable; PR, partial response (PSA level > 0.2 but < 4 ng/ml.); PSA, Prostate Specific Antigen